Aurinia Pharmaceuticals Inc.

General Information

Company Name

Founded Year

2013

Location (Offices)

Edmonton, Canada +3

Founders / Decision Makers

Number of Employees

256

Industries

Biopharma, Biotechnology, Health Care +1

Funding Stage

Post Ipo Equity

Social Media

Aurinia Pharmaceuticals Inc. - Company Profile

Aurinia Pharmaceuticals Inc. is a Canadian biopharmaceutical company founded in 2011. The company is focused on addressing autoimmune diseases through innovative scientific research. Aurinia recently received a major investment of $200.00M in post-IPO equity funding on 22 July 2020. This significant investment demonstrates the confidence of the investor community in Aurinia's potential to make a meaningful impact in the biopharma, biotechnology, and healthcare industries. With a commitment to rigorous science and breakthrough treatments, Aurinia is well-positioned to drive advancements in addressing some of the most challenging autoimmune diseases. For more information, visit their website.

Taxonomy: autoimmune disease, medical science, pharmaceuticals, community guidelines, public engagement, patient education, scientific research, health information, regulatory compliance, online community management

Funding Rounds & Investors of Aurinia Pharmaceuticals Inc. (7)

View All

Funding Stage	Amount	No. Investors	Date
Post-IPO Equity	$200.00M	-	22 Jul 2020
Post-IPO Equity	$191.70M	-	12 Dec 2019
Post-IPO Equity	$173.10M	-	20 Mar 2017
Post-IPO Equity	$28.75M	-	28 Dec 2016
Post-IPO Equity	$7.08M	-	15 Jun 2016